Global Artificial Blood Vessels Market Growth Prospects 2024-2032

Global Artificial Blood Vessels Market Growth Prospects 2024-2032

According to Triton Market Research’s report, the Global Artificial Blood Vessels Market is expected to advance with a CAGR of 6.89% during the forecast period 2024-2032.

ARTIFICIAL BLOOD VESSELS MARKET ANALYSIS

Artificial blood vessel materials are synthetic constructs designed to replicate the function of natural blood vessels, providing essential pathways for blood flow in cases where natural veins or arteries are damaged or diseased. Artificial veins and artificial arteries are created using various blood vessel replacement materials, including polymers and biocompatible materials, often employing advanced technologies like 3D printing artificial blood vessels. These synthetic vessels are crucial for treating cardiovascular diseases, which are the leading cause of death globally, responsible for approximately 17.9 million deaths each year, according to the World Health Organization (WHO).

The demand for artificial blood vessels is on the rise, driven by the need for reliable solutions in conditions like coronary artery disease, peripheral artery disease (PAD), and end-stage renal disease (ESRD). The growing aging population exacerbates this need, as aging significantly heightens the risk of cardiovascular diseases and vascular complications. With the global population aged 65 and over projected to nearly double by 2050, the market for synthetic vascular grafts is expanding rapidly, driven by the increasing requirement for effective, durable vascular replacements.

ARTIFICIAL BLOOD VESSELS MARKET PERFORMANCE: DRIVERS, CHALLENGES, AND OPPORTUNITIES

Growing Geriatric Population and Changing Lifestyles

The increasing prevalence of cardiovascular diseases (CVDs) and vascular disorders, combined with shifting demographics and lifestyle changes, is significantly driving the demand for artificial blood vessels in the global market. As the population’s age and lifestyle-related health issues such as obesity, diabetes, and sedentary behaviors become more common, the need for effective vascular interventions and grafts is growing. These trends are leading to a higher demand for artificial blood vessels to address conditions like atherosclerosis, coronary artery disease, and peripheral artery disease.

The aging global population plays a crucial role in the rising prevalence of cardiovascular diseases and vascular disorders. According to the United Nations, the number of people aged 65 and over is expected to double from 734 million in 2020 to 1.5 billion by 2050. This demographic shift increases the susceptibility of older individuals to vascular conditions that often require surgical interventions involving artificial blood vessels. Additionally, the growing incidence of end-stage renal disease (ESRD), partly due to an aging population and higher rates of diabetes, is also contributing to the increased need for artificial blood vessels, particularly for patients undergoing hemodialysis.

Stringent Regulatory Approvals and Clinical Trial Requirements

Stringent regulatory approvals and clinical trial requirements are essential to ensure the safety and efficacy of artificial blood vessels. However, these processes can also create significant challenges in terms of time, cost, and resource allocation. Artificial blood vessels are classified as high-risk medical devices in many regulatory jurisdictions, including the United States and the European Union. This classification subjects them to rigorous scrutiny and extensive testing before they can be approved for commercial use. In the United States, for instance, the Food and Drug Administration (FDA) regulates these devices under the Premarket Approval (PMA) pathway, which requires a thorough review of preclinical and clinical data to assess safety and effectiveness.

The clinical trial requirements for artificial blood vessels are particularly demanding, often involving multiple phases that must demonstrate the device’s performance, durability, and potential for adverse events over an extended period. These trials can span several years, necessitating significant financial investment, specialized expertise, and a large patient population. Additionally, recruiting and retaining participants for these trials can be challenging due to the high-risk nature of the procedures involved. The complexity and length of these trials add to the overall cost and time required for bringing artificial blood vessels to market, posing significant barriers for manufacturers.

Development of 3D Bioprinting Techniques for Customized Vascular Grafts

Artificial blood vessels have traditionally relied on synthetic materials or cadaveric vessels, which can present limitations such as reduced durability and an increased risk of complications. However, advances in 3D bioprinting techniques provide an alternative by enabling the creation of patient-specific, biocompatible vascular grafts that are tailored to individual anatomical needs. For example, researchers at the University of Minnesota successfully bioprinted a life-sized model of a patient’s cardiovascular system, paving the way for the production of customized vascular grafts that closely mimic the structures and properties of natural blood vessels.

Another notable development is a collaborative project between the University of Toronto and the Hospital for Sick Children, where researchers used 3D bioprinting to create living vascular grafts by depositing patient-derived cells onto a biodegradable scaffold. This method facilitates seamless integration with the recipient’s body, offering a more personalized and potentially more successful treatment option. The main advantage of 3D bioprinting lies in its ability to replicate the complex geometries and anatomical features of blood vessels with precision. By using advanced imaging techniques and patient-specific data, bioprinted vascular grafts can be customized to fit the unique vascular anatomy of each recipient, potentially reducing the risk of complications and improving surgical outcomes.

GLOBAL ARTIFICIAL BLOOD VESSELS MARKET REPORT SEGMENTATION

Market by Type:

• Expanded Polytetrafluoroethylene (ePTFE)
• Polyurethane
• Polyethylene Terephthalate (PET)
• Other Types

Expanded Polytetrafluoroethylene (ePTFE) is a synthetic fluoropolymer used in artificial blood vessels. Its microporous structure, consisting of interconnected nodes and fibrils, supports tissue ingrowth and improves biocompatibility. This structure allows ePTFE to mimic the properties of natural blood vessels, promoting blood flow and reducing the risk of thrombosis or occlusion. It is chemically resistant, making it inert to bodily fluids and substances, which helps ensure its durability in long-term implants. It also has tensile strength and flexibility, allowing it to endure the pressures of the cardiovascular system. Manufacturing techniques like stretching, sintering, and surface modifications are employed to enhance the surface characteristics of ePTFE grafts.

Market by Blood Vessel Diameter:

• Large
• Medium
• Small

Large artificial blood vessel grafts, which typically range in diameter from 6 mm to 30 mm or more, are designed to replace or bypass major blood vessels such as the aorta, iliac arteries, or femoral arteries. These grafts are constructed to handle the pressures and flow rates associated with the cardiovascular system’s larger vessels. They are often employed in procedures like aortic aneurysm repair, where a portion of the aorta is substituted with a synthetic graft. The selection of the appropriate graft material and design for large blood vessel applications is influenced by factors such as the specific location and diameter of the vessel being replaced, expected blood flow rates and pressures, and the patient’s characteristics.

Market by Patient Demographics:

• Adult
• Pediatric

Market by Application:

• Aortic Disease
• Peripheral Artery
• Hemodialysis

Market by End-User:

• Hospital
• Specialty Clinics
• Ambulatory Surgical Center
• Other End-User

KEY ARTIFICIAL BLOOD VESSELS COMPANIES INSIGHTS

The companies’ insights help dive into data about the key players in the artificial blood vessels market. The strategic initiatives for each of the companies considered have been covered in detail. Some of the key strategic initiatives are:

Acquisition (January 2020): Getinge and Applikon Biotechnology

In January 2020, Getinge acquired Applikon Biotechnology, a company specializing in the development and supply of advanced bioreactor systems for the research and production of vaccines and antibodies in the biopharmaceutical industry, as well as enzymes and bio-plastics for industrial biotechnology.

Acquisition (December 2021): Becton, Dickinson and Company and Venclose Inc

Becton, Dickinson and Company acquired Venclose Inc, expanding its portfolio to include solutions for chronic venous insufficiency (CVI) treatment. Venclose’s Radio Frequency (RF) ablation technology platform addressed a significant therapeutic need, impacting up to 40% of women and 17% of men in the United States.